Evidence map›Paper›PMID 32911536›Full record

ArticleBlood2020

An intact gut microbiome protects genetically predisposed mice against leukemia.

Carolina Vicente-Dueñas, Stefan Janssen, Marina Oldenburg, Franziska Auer, Inés González-Herrero, Ana Casado-García, Marta Isidro-Hernández, Javier Raboso-Gallego, Philipp Westhoff, Aleksandra A Pandyra and 13 more

Open access · bronzeAbstract read
In one paragraph

Article in Blood, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 101 citations in OpenAlex.

  1. Randomized Double-Blind Phase II Trial of Fecal Microbiota Transplantation Versus Placebo in Allogeneic Hematopoietic Cell Transplantation and AML.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Trial
  2. Article
  3. Review
  4. The Role of Gut Microbiota in Acute Myeloid Leukemia.Journal of clinical medicine · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 9 institutions in 3 countries.

Carolina Vicente-DueñasInstitute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Stefan JanssenPediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
Marina OldenburgPediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
Franziska AuerGerman Cancer Research Center (DKFZ), Heidelberg, Germany.
Inés González-HerreroInstitute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Ana Casado-GarcíaInstitute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Marta Isidro-HernándezInstitute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Javier Raboso-GallegoInstitute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Philipp WesthoffInstitute of Plant Biochemistry, Cluster of Excellence on Plant Science, Heinrich Heine University, Düsseldorf, Germany.
Aleksandra A PandyraPediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
Daniel HeinPediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
Katharina L GösslingPediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
Diego Alonso-LópezBioinformatics Unit, and.
Javier De Las RivasInstitute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Sanil BhatiaPediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
Francisco Javier García-CriadoInstitute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
María Begoña García-CenadorInstitute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Andreas P M WeberInstitute of Plant Biochemistry, Cluster of Excellence on Plant Science, Heinrich Heine University, Düsseldorf, Germany.
Karl KöhrerBiological and Medical Research Center, Genomics and Transcriptomics Laboratory, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Julia HauerNational Center for Tumor Diseases (NCT), Dresden, Germany: and.
Ute FischerPediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
Isidro Sánchez-GarcíaInstitute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Arndt BorkhardtPediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
Heinrich Heine University Düsseldorf · DEConsejo Superior de Investigaciones Científicas · ESCluster of Excellence on Plant Sciences · DEInstituto de Investigación Biomédica de Salamanca · ESUniversidad de Salamanca · ESBioinformatics Institute · SGGerman Cancer Research Center · DEJustus-Liebig-Universität Gießen · DENational Center for Tumor Diseases · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The majority of childhood leukemias are precursor B-cell acute lymphoblastic leukemias (pB-ALLs) caused by a combination of prenatal genetic predispositions and oncogenic events occurring after birth. Although genetic predispositions are frequent in children (>1% to 5%), fewer than 1% of genetically predisposed carriers will develop pB-ALL. Although infectious stimuli are believed to play a major role in leukemogenesis, the critical determinants are not well defined. Here, by using murine models of pB-ALL, we show that microbiome disturbances incurred by antibiotic treatment early in life were sufficient to induce leukemia in genetically predisposed mice, even in the absence of infectious stimuli and independent of T cells. By using V4 and full-length 16S ribosomal RNA sequencing of a series of fecal samples, we found that genetic predisposition to pB-ALL (Pax5 heterozygosity or ETV6-RUNX1 fusion) shaped a distinct gut microbiome. Machine learning accurately (96.8%) predicted genetic predisposition using 40 of 3983 amplicon sequence variants as proxies for bacterial species. Transplantation of either wild-type (WT) or Pax5+/- hematopoietic bone marrow cells into WT recipient mice revealed that the microbiome is shaped and determined in a donor genotype-specific manner. Gas chromatography-mass spectrometry (GC-MS) analyses of sera from WT and Pax5+/- mice demonstrated the presence of a genotype-specific distinct metabolomic profile. Taken together, our data indicate that it is a lack of commensal microbiota rather than the presence of specific bacteria that promotes leukemia in genetically predisposed mice. Future large-scale longitudinal studies are required to determine whether targeted microbiome modification in children predisposed to pB-ALL could become a successful prevention strategy.

Indexed as

Disease SusceptibilityGastrointestinal MicrobiomeAnimalsDysbiosisFecesFemaleLeukemia, ExperimentalMiceMice, Inbred C57BLMice, KnockoutPAX5 Transcription FactorPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPax5 protein, mousePAX5 Transcription Factor

Identifiers

PMID32911536
PMCPMC7694022
OpenAlexW3086420584

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.